科研动态PubMed 摘要
[不可用]。
PubMed 白名单日捞 · 2026-01-01
完整摘要 · 中文译文
FitPreV评估了将多基因风险评分和可穿戴健康设备整合到全科医疗心血管一级预防中的可行性。在这项四臂试点随机试验中，120名患有代谢综合征的成年人被随访12个月。招募率较高，可接受性良好，多基因风险评分（Prs）披露后焦虑程度较低。然而，12个月随访的完整性和全科医生实施该干预措施的意愿仍需改善。
完整摘要 · 英文原文
FitPreV assessed the feasibility of integrating polygenic risk scores and wearable health devices into cardiovascular primary prevention in general practice. In this four-arm pilot randomized trial, 120 adults with metabolic syndrome were followed for 12 months. Recruitment was high and acceptability was favourable, with low anxiety after polygenic risk score (Prs) disclosure. However, 12-month follow-up completeness and GP willingness to implement the intervention require improvement.
English
[Not Available].